Member Info for PM2022

Looking forward to the next Q and A which should this month.

You need some experience. It is a bit like building a house you don't knock it all down and build again with non builders maybe doctors acting as builders trying to build a house with no help and needing all the money to build from scratch which means more placings and destruction. You lose everything if that happens that is if people are really invested.

Personally I would keep Suzy and Kevin for now as if you will put people on with little experience then you need experience to go with that whether you like it or not. You have to build on what you have.

The better solution would have been to have the two new non execs joining who have experience then making improvements later but that never happened.

Market Cap is 3.89 million. I look at it relative to the valuation. I think the good part here is that we will not get placings to invest in other projects so what we have now should add value eventually.

Blue Star has been an investor in SatoshiPay since 2017 and has a shareholding of 27.9 per cent. Based on the last external funding round that took place between February and May 2019, SatoshiPay was valued at ?19.2 million.

Our market cap is 3.89 Million. So Satoshipay would need to be worth just about 13/14 million which is far lower than 2017.

I think Dynasty will be easier to judge and far easier to sell a stake or get a valuation if they go into India. I would be confident then can sell at an over inflated price but this might be a few months away.

You just have to buy and hold at these prices imo. Updates will come so the base should increase overtime. Satoshi will get sold or they will get a valuation I am sure soon so it doesn't need to be worth much for this to rocket. If it is worth more than 2017 which is likely then potential gains are very significant if you then factor in Dynasty.

We will likely get a dividant at some point as well. A good hold and buy but as long as you are happy to wait then I think a few 100% will be on offer at these prices.

Cause it will. It takes about 6 months to complete a merger so I am sure that would be ongoing with Googly before an announcement comes.

India has many wealthy investors, many billionaires and I am next to certain some will pay for a stake in Dynasty/googly. Once the merger completes then it would be easy to get a sale price and a valuation.

Quiet period but I see Blue hitting 0.50p this year for sure. Not much downside so a good buy at these levels. I added this morning and will add more later.

Mr Porky but you are not invested. You would be happy to buy at 0.000001p makes no difference to you.

Talk about what is good for current holders that will lead to a higher share price in the shorter term.

We don't want the new guys to get confused now do we.

6/7 new projects H2. It all depends how good a project is It is so hard to find good ones. You don't get potential new science sitting everywhere. Who will pay for 6/7 projects then if half of those progress to preclinical what then? how are you going to fund so many new projects at the same time. If they are junk then 5/6 failures will drop the SP and drop confidence yet again.

Also no point messing around with 201 patents nobody gonna pay for it and waste all that time. All it is doing is dropping the SP even further down for others buying at 1p to benefit not us.

Calling for a raise then asking for a new BOD is only going to make people not want to vote for it. Exactly my argument and why I don't like what is proposed. It needs to build on what they have not have not knocked all the way down and start again.

Your going down the exact strategy 4D had and failed.

Mergers take between 2 months and 12 months with the average being 6/7 months. I think they were little further than the start of the talks when LOI was announced and given it has been ongoing then you would expect it to conclude.

Val still needs 201 because without that then we are looking at a lower placing price when it happens which will end it for existing holders. Only 201 or maybe CLX will recover us to double figures at the moment.

Not happy with the performance of Kevin but if they can provide some clarity then I would have to reluctantly back them as destroying everything and starting again will take too much time and a few more placings at lower prices imo than what the current BOD would do imo.

Lack of placing experience is also a concern of mine as it will be needed so how will these guys conduct that. You cannot rely on the broker, it will be a complete mess imo.

The best solution remains a compromise maybe 1/2 shareholders can join the board.

Agree totally. The current BOD is not a great fit as they don't have an incentive to take the share price up and they do hold large amounts so it matters not to them if they came back for a placing.

At the same time you cannot just put a bunch of business minded people on the board as you need to understand the process or negotiating a deal in this field, getting lab contracts and building the science side of the business.

It needs a combination of both in my view.

The extreme left vs extreme right. You need the right balance with real shareholders on the board with AIM biotech experience. You need people that know how to strike a deal and know how that all works.

I would have got Adam in even if it meant just an hour or two a week. Popular choice and good for the share price and with that we would be happy to allow them options so everyone wins.

Shareholder action group wanted change so some were driven out imo.

Can't win if you make a replacement the derampers moan if you don't they want changes but then again most here are not even invested so not sure why they come. Must see potential.

And takeovers.

SAR hit a market cap of 300 million at one point which was too high for that stock. Stocks go up and down but as long you understand the market and know how to play it. Maybe allow them achievable short term targets through options say at 15 p before August 2024 and see what can happen.

He looks like he has strong commercial skills which is what is needed. Hopefully he might help secure a deal for CLX this year.

It can only be positive as the current guys will have to prove themselves to the new guys.

37 million MC is already very high for what they have so any rise is great. A few weeks ago it was higher. Looks to be already priced into the mc which is one reason we should be positive.

EUDA UP 9%.

I believe the merger is provisionally agreed.

My guess on the delay is that TRX are doing some reformulation work on 201 and funding has been successful. I could be wrong but I am aware this was a step that needed to be done before the sub-licence was signed and after funding.

Whatever plans they had after funding for 201 it would need executing before EUDA agrees to the merger. You cannot agree with the merger if this step is not complete if 201 plays a big role in the merger completion.

Maybe the next stage is the application for updated patent if the science is put into practise, merger success then signing the sub license soon after. Not sure about the process though.

If I am right then it would seem the merger should very likely be signed soon. That would explain why Suzy and co are so confident as they would have an idea of the plans TRX are executing.

Is this relevant?

https://www.globenewswire.com/news-release/2024/02/22/2833665/0/en/Introducing-SatoshiSwap-pioneer-decentralized-exchange-built-on-the-Bitcoin-network.html

Thank you. Agree and we cannot keep funding it but I understand the need for the lab given the strategy. The expectation was that the lab would be self funded and eventually it might be but no point if it takes 10 placings to get to that level.

I think it has proven we were right to vote no to resolution 4 last year as if they went and purchased more at the time we would have been bust now as they generated nothing of value.

I still believe 201 and CLX will be a maker here but progress has been slow so we need to see more soon and that needs to reflected in the share price.

Productivity would likely be slow if all the non-lab staff are all working from home because Suzy took the office to Nuneaton. Maybe they are all at home eating doughnuts. If staff cannot work from home and produce results then they need to commute to Nuneaton everyday. This is where good management comes in.

The problem is with a new CEO, how will they fund all the extras that are needed given where the office is. Our share price at the moment cannot pay for all that otherwise any future placing will be high.

Not sure what Andrew and Gareth are doing given the lab has not done much so far other than it being set up for the last year. Are they not supposed to be bringing business in.

What happened to all the old Imogen clients when they were generating millions? Very Bizarre but hopefully 201 will complete soon.

With the potential milestones but not upfront. I have posted an article in the past not going to bother digging it up now.

Still you can get some very large upfront payments at pre clinical level.

It is more valuable for the shareholders given clinical trials cost so much. Otherwise Valirx would be burning 10,20,30,40 50 million a year not less than 2 million.

Why do you care? You say you have no intention to invest or have not done so in the past just that you refused a chance in the past.

The strategy is not to do clinical trials. It is to get deals for preclinical compounds so no peer reviews needed. Clinical trials are what causes huge dilutions and consolidations due to costs and the largest deals tend to be at preclinical level.

You keep mentioning the same thing about 201 all that matters is the funding for phase 2b trials, payments and agreed milestones. The rest can happen after larger trials. That is for others to worry about who are paying for it the next stages.